Clinical Trial Update: A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

Phase 3 study evaluating satralizumab in generalized myasthenia gravis was terminated. Results from the trial have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Satralizumab (satralizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Generalized Myasthenia Gravis | Phase 3 | Status: TERMINATED | Results posted: 2025-02-28